TY - JOUR
KW - Adolescent
KW - Adolescent Behavior/psychology
KW - Humans
KW - Opiate Substitution Treatment/psychology
KW - Opioid-Related Disorders/drug therapy
KW - Social Stigma
AU - Sarah M. Bagley
AU - Scott E. Hadland
AU - Brittany L. Carney
AU - Richard Saitz
A1 - 
AB - : In September 2016, the American Academic of Pediatrics released a policy statement that adolescents with opioid use disorder should be offered pharmacotherapy with buprenorphine/naloxone, methadone, or naltrexone. In our clinical practice, however, we have encountered the perception among patients, families, and clinicians alike that medications should be used as a last resort. That we should wait until things get worse is a discarded approach. As addiction specialists, it is imperative that we prevent and identify risky use and use disorders, then intervene early and offer timely, evidence-based treatment. We suggest that adolescents deserve special attention and that specific efforts should be made to reduce the stigma associated with treating adolescents with opioid use disorder with medications to optimize those efforts.
AD - Department of Medicine, Boston University School of Medicine, Boston, MA (SMB, RS); Department of Pediatrics, Boston University Schoolf of Medicine, Boston, MA (SMB, SEH); Boston Medical Center, Boston, MA (SMB, SEH, BLC, RS); Department of Community Health Sciences, Boston University School of Public Health, Boston, MA (RS).
BT - Journal of addiction medicine
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CP - 6
CY - United States
DO - 10.1097/ADM.0000000000000348
IS - 6
JF - Journal of addiction medicine
LA - eng
M1 - Journal Article
N2 - : In September 2016, the American Academic of Pediatrics released a policy statement that adolescents with opioid use disorder should be offered pharmacotherapy with buprenorphine/naloxone, methadone, or naltrexone. In our clinical practice, however, we have encountered the perception among patients, families, and clinicians alike that medications should be used as a last resort. That we should wait until things get worse is a discarded approach. As addiction specialists, it is imperative that we prevent and identify risky use and use disorders, then intervene early and offer timely, evidence-based treatment. We suggest that adolescents deserve special attention and that specific efforts should be made to reduce the stigma associated with treating adolescents with opioid use disorder with medications to optimize those efforts.
PP - United States
PY - 2017
SN - 1935-3227; 1932-0620
SP - 415
EP - 416
EP - 
T1 - Addressing Stigma in Medication Treatment of Adolescents With Opioid Use Disorder
T2 - Journal of addiction medicine
TI - Addressing Stigma in Medication Treatment of Adolescents With Opioid Use Disorder
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U2 - 28767537
U3 - 10.1097/ADM.0000000000000348
VL - 11
VO - 1935-3227; 1932-0620
Y1 - 2017
Y2 - Nov/Dec
ER -